Rollercoaster of Hospital COVID Drug Spending Continued in 2022
May 10th 2023Using a national database, data on medication purchases was collected, along with factors that may have influenced expenditures, such as new therapy availability, patent expirations, policy changes, and legislation.
Read More
FDA Approves First Fecal Microbiota Pill for Recurrent C. diff Infection
April 28th 2023CDI is a leading cause of infections acquired in healthcare settings, including hospitals and nursing homes. After recovering, individuals may get the infection again, and the risk of recurrence increases with each infection.
Read More
HyQvia Receives Expanded FDA Approval for Pediatric Primary Immunodeficiency
April 14th 2023HyQvia is the first FDA-approved treatment for primary immunodeficiency (PI) available as a once-a-month subcutaneous injection. Other treatments for PI, while similarly effective, present a greater burden to patients, often requiring more frequent injections or more invasive routes of administration
Read More
FDA Grants Emergency Use Authorization to Gohibic for Critically Ill COVID-19 Patients
April 6th 2023The FDA granted the EUA based on the PANAMO phase 3 clinical trial results demonstrating that vilobelimab improved survival compared to placebo, with a 23.9% relative reduction in all-cause mortality at 28 days.
Read More